Meeting the medical need for advanced NET therapies
NETs (NeuroEndocrine Tumors) are a heterogeneous group of tumors originating in the neuroendocrine cells of the body. The unmet medical need for an effective treatment of inoperable, advanced NETs is well known. More specifically, there is no therapeutic options for patients with NETs other than pancreatic (about 90% of NETs) who are progressive under somatostatin analogues.
In Molecular Nuclear Therapy, a radioisotope is attached to a “targeting molecule”. This molecule brings the radioisotope in the tumor cells where its energy will be released and destroy targeted tissues.
Our lead investigational candidate, 177Lutetium Dotatate, is a novel compound in development for the treatment of midgut neuroendocrine tumors. Lutathera is a somatostatin analogue peptide (the “targeting molecule”) which has been labeled with Lutetium-177 (the radioisotope). Upon injection, 177Lutetium Dotataterapidly binds to neuroendocrine tumors where it releases its energy in a targeted manner, it is then rapidly cleared from the body via urines.
Results of a pivotal Phase III trial of 177Lutetium Dotatate in patients with inoperable progressive midgut NETs were published in the New England Journal of Medicine and 177Lutetium Dotatate is currently made available through compassionate use/named patient basis programs in ten selected European countries (Austria, Denmark, Estonia, Finland, France, Greece, Portugal, Spain, Switzerland and UK) and the U.S.